Business Segments
Where we work.
Amigen operates across a broad range of healthcare segments — from established pharmaceutical categories to advanced therapies, medical devices, and health supplements. Our coverage reflects the full scope of what global and regional partners need to bring to emerging markets.
Broad coverage. Deep execution.
Our segment coverage is not opportunistic — it is built around the realities of what emerging market patients need and what our regulatory, commercial, and supply chain capabilities can support. We work across pharmaceuticals, biotech, medical devices, and advanced healthcare solutions.
Whether you are an originator, a CDMO, a CMO, or a regional distributor, we can structure and execute the right market entry model for your product category. Specific products, regulatory timelines, and licensing terms are disclosed only to prospective partners under appropriate confidentiality arrangements.
Portfolio
Current areas of focus.
Oncology & Hematology
Bringing proven cancer therapies closer to patients.
Cancer is among the leading causes of mortality across the Middle East and Africa, yet access to approved targeted therapies, immunotherapies, and haematological treatments remains severely limited. We actively pursue in-licensing and business development opportunities for oncology and haematology products with established efficacy profiles in reference markets.
Active pipeline. Specific products not disclosed.
Biologics & Biosimilars
Expanding access to biological medicines.
Biologics and biosimilars represent one of the fastest-growing segments in global healthcare, yet their penetration in emerging markets remains low due to regulatory complexity and supply chain requirements. Amigen supports the registration, licensing, and commercialisation of biological medicines — including biosimilars where cost-effective access is the primary driver.
Active pipeline. Specific products not disclosed.
Rare Diseases & Orphan Drugs
Orphan therapies for underserved patient populations.
Patients with rare diseases in emerging markets face a compounded disadvantage: their conditions are underdiagnosed, and the therapies that exist are rarely registered locally. We build rare disease portfolios focused on conditions with established genetic prevalence in our target populations and approved treatments in reference markets.
Active pipeline. Specific products not disclosed.
Cardiology & Nephrology
Closing the gap in cardiovascular and renal care.
Cardiovascular disease is the leading cause of death globally and disproportionately affects populations in emerging markets. Renal disease burden is similarly high and undertreated. We support the registration and commercialisation of approved therapies in lipid management, heart failure, anticoagulation, and renal conditions.
Active pipeline. Specific products not disclosed.
Central Nervous System
Neurological conditions with significant unmet need.
Neurological disorders — including multiple sclerosis, epilepsy, and neuromuscular diseases — represent a growing area of unmet need across the Middle East and Africa. We are evaluating the regulatory landscape and licensing opportunities for approved CNS therapies not yet available in our target markets.
Under evaluation. No active licensing at this time.
Women's Health & Endocrinology
Addressing the chronic disease burden of the region.
The Middle East carries one of the highest global burdens of diabetes, obesity, and related metabolic conditions. Women's health remains significantly underserved across our target geographies. We pursue registration of endocrinology and women's health therapies that are standard of care in established markets but not yet accessible locally.
Active pipeline. Specific products not disclosed.
Infectious Diseases & Vaccines
Proven infectious disease solutions for high-burden markets.
Infectious disease burden remains disproportionately high across Sub-Saharan Africa, Southeast Asia, and parts of MENA. We support the licensing, registration, and supply chain development of approved anti-infective therapies and vaccines — including both novel agents and established treatments not yet accessible in target markets.
Active pipeline. Specific products not disclosed.
Specialty Injectables & Plasma Products
Complex injectables and plasma-derived therapies.
Specialty injectables and plasma-derived products require sophisticated regulatory handling, cold-chain supply chains, and specialist commercial infrastructure. Amigen's capabilities in regulatory execution and supply chain development make us a natural partner for companies seeking to bring these products to emerging markets.
Active pipeline. Specific products not disclosed.
Health Supplements
Nutraceuticals and health supplements for growing markets.
Consumer health and nutraceutical markets across MENA and Africa are growing rapidly, driven by rising health awareness and expanding middle-class populations. We support the registration, licensing, and distribution of health supplements and nutraceutical products across our geographies.
Active. Specific products not disclosed.
APIs
Active pharmaceutical ingredient sourcing and supply.
Access to quality-assured APIs is a critical enabler for local pharmaceutical manufacturing across emerging markets. Amigen supports API sourcing, supply chain structuring, and trading arrangements — connecting global API manufacturers with regional formulators and manufacturers who need reliable, compliant supply.
Active. Enquiries welcome.
Medical Devices
Bringing innovative medical devices to emerging markets.
Medical device access in emerging markets lags significantly behind the clinical need. Amigen supports the registration, licensing, and commercialisation of medical devices — from diagnostics and surgical instruments to digital health solutions — applying the same regulatory rigour and commercial discipline we bring to pharmaceuticals.
Active. Specific products not disclosed.
Advanced Therapies
Preparing for the next generation of healthcare.
Advanced therapy medicinal products — including cell therapies, gene therapies, and tissue-engineered products — represent the frontier of pharmaceutical innovation. While regulatory pathways in emerging markets are still maturing, Amigen is actively monitoring the landscape and building the expertise to support partners as these therapies move toward broader global access.
Under evaluation. Regulatory landscape monitoring ongoing.
Portfolio transparency.
Amigen does not publish a detailed public portfolio. Specific products, regulatory timelines, and licensing terms are disclosed only to prospective partners under appropriate confidentiality arrangements. If you represent a company with a product seeking emerging market entry across any of our segments, we welcome a direct conversation.
A product in one of these segments?
Whether you are a pharmaceutical originator, a CDMO, a CMO, or a medical device company — if you have a product ready for emerging market entry, we should talk.